274 related articles for article (PubMed ID: 35304677)
1. Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis.
Guan Y; Shen G; Fang Q; Xin Y; Huo X; Li J; Zhao F; Ren D; Liu Z; Li Z; Zhao J
Clin Exp Med; 2023 Jun; 23(2):245-254. PubMed ID: 35304677
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Guo S; Jin F; Zheng A
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37283514
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.
Hong K; Yao L; Sheng X; Ye D; Guo Y
Oncol Res Treat; 2021; 44(10):557-567. PubMed ID: 34515204
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
5. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
6. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Dubsky PC; Singer CF; Egle D; Wette V; Petru E; Balic M; Pichler A; Greil R; Petzer AL; Bago-Horvath Z; Fesl C; Meek SM; Kronenwett R; Rudas M; Gnant M; Filipits M;
Eur J Cancer; 2020 Jul; 134():99-106. PubMed ID: 32502940
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials.
Gao HF; Lin YY; Zhu T; Ji F; Zhang LL; Yang CQ; Yang M; Li JQ; Cheng MY; Wang K
Breast; 2021 Oct; 59():165-175. PubMed ID: 34271289
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
Dai Q; Wang Y; Liao M; Chen H
Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
[TBL] [Abstract][Full Text] [Related]
9. Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2- advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Yang L; Xue J; Yang Z; Wang M; Yang P; Dong Y; He X; Bao G; Peng S
Ann Palliat Med; 2021 May; 10(5):5590-5599. PubMed ID: 34107710
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials.
Munzone E; Pagan E; Bagnardi V; Montagna E; Cancello G; Dellapasqua S; Iorfida M; Mazza M; Colleoni M
ESMO Open; 2021 Dec; 6(6):100332. PubMed ID: 34864350
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 Inhibitors in Combination With Hormone Therapy for HR
Deng Y; Ma G; Li W; Wang T; Zhao Y; Wu Q
Clin Breast Cancer; 2018 Oct; 18(5):e943-e953. PubMed ID: 29804650
[TBL] [Abstract][Full Text] [Related]
12. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis.
Agostinetto E; Vian L; Caparica R; Bruzzone M; Ceppi M; Lambertini M; Pondé N; de Azambuja E
ESMO Open; 2021 Apr; 6(2):100091. PubMed ID: 33743330
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study.
Wang X; Fan Z; Wang X; He Y; Liu Y; Wang X; Zhang B; Jiang Z; Wang T; Yu Z; Wang F; Liu Y; Li Y; Zhang J; Luo B; Jiang H; Wang T; Xie Y; Li J; Ouyang T
Breast Cancer Res Treat; 2022 Oct; 195(3):301-310. PubMed ID: 35917052
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
Han Y; Wang J; Wang Z; Xu B
Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
[TBL] [Abstract][Full Text] [Related]
16. Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Martel S; Bruzzone M; Ceppi M; Maurer C; Ponde NF; Ferreira AR; Viglietti G; Del Mastro L; Prady C; de Azambuja E; Lambertini M
Cancer Treat Rev; 2018 Jan; 62():123-132. PubMed ID: 29108713
[TBL] [Abstract][Full Text] [Related]
17. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
20. The effect and safety of CDK4/6 inhibitors combined endocrine therapy on HR+, HER2-breast cancer: a meta-analysis of randomized controlled trials.
Huang T; He Y; Yu C; Mao F; Si Y
Endokrynol Pol; 2023; 74(1):89-105. PubMed ID: 36704980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
